Overview of Osurnia

Property	Description
Active Ingredients	Florfenicol, Terbinafine, Betamethasone Dipropionate
Form	Otic Gel (Translucent Gel)
Pharmacological Class	Antibiotic, Antifungal, Glucocorticosteroid (Combination)
Route of Administration	Otic (Topical into the ear canal)
Origin	Synthetic

What Type of Veterinary Medicine is Osurnia?

Osurnia is defined as a prescription veterinary medicinal product developed as a fixed combination otic gel for topical administration exclusively in dogs. The product is synthetic in origin and is categorized as a multi-action pharmaceutical, requiring a professional veterinary prescription for its dispensing and use. The formulation's primary identity as an adaptable gel is a key differentiating feature; it is specifically designed for prolonged adherence to the complex and often inflamed surfaces of the external ear canal.

The Triple-Active Composition of Osurnia

The unique identity of Osurnia rests on its triple-active composition, which integrates three distinct active ingredients, each belonging to a separate pharmacological class. These ingredients are the antibiotic Florfenicol, the antifungal Terbinafine (Terbinafine Hydrochloride), and the potent glucocorticosteroid Betamethasone Dipropionate. This integration results in a fixed-dose product that combines antibacterial, antifungal, and anti-inflammatory properties. The use of a multi-component therapy like this is intended for instances where ear distress involves mixed microbial populations and significant inflammation.

General Purpose: Comprehensive Microbial and Inflammatory Control

Osurnia's general therapeutic purpose is to provide simultaneous anti-infective and anti-inflammatory action to address the complex nature of common ear distress in canines. The formulation is intended to provide comprehensive control over microbial proliferation, specifically targeting susceptible bacterial organisms and fungal organisms, such as yeast. Concurrently, the glucocorticosteroid component works to relieve the intense inflammation, painful swelling, and severe pruritus (itching) that often accompany these microbial issues. This approach provides relief by targeting the root causes of infection and the associated discomfort simultaneously.

Regulatory References

U.S. Food and Drug Administration (FDA)

What side effects are possible with Osurnia?

Possible Side Effects and Safety Information

The safety profile for Osurnia (Florfenicol, Terbinafine, Betamethasone otic gel) is defined by officially documented adverse reactions, frequency classifications, and use constraints detailed in regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions observed in clinical trials are classified by incidence. The most common reactions reported were Elevated Alkaline Phosphatase (ALP) and Vomiting. Less common reactions included elevated liver enzymes (AST, ALT, and/or ALP), temporary hearing decrease/loss, and weight loss of over ten percent of body weight.

Post-authorization surveillance documents certain reactions as very rare (less than 1 in 10,000 animals treated). These involve the Ear and Labyrinthine Disorders, such as deafness, tympanic rupture, and internal ear disorders (e.g., head tilt). Other very rare serious reactions include ataxia, facial paralysis, and ocular effects like Keratoconjunctivitis Sicca (KCS).

Systemic and Population-Specific Safety Constraints

Regulatory documentation confirms the systemic absorption of the Betamethasone component, which may lead to measurable adrenocortical suppression and potential for iatrogenic hyperadrenocorticism following prolonged or intensive use. This effect has been noted to be reversible.

The medication is strictly contraindicated in dogs with a known tympanic perforation (ruptured eardrum). Its safe use has not been established in certain populations, including dogs less than two months of age, those weighing less than 1.4 kg, dogs used for breeding purposes, or pregnant or lactating bitches. Use requires particular caution in dogs with impaired hepatic function or known endocrine disorders.

Overdose and Emergency Response

The official regulatory profile for an overdose of this combination otic gel is structured around the potential for systemic effects and mandated emergency responses for accidental human exposure.

Documented Manifestations and Systemic Risk

High or prolonged exposure carries the potential for systemic effects due to the corticosteroid component. Overexposure is specifically associated with the potential for suppression of adrenal function, which is an endocrine system effect often indicated by reduced serum cortisol levels and pathological changes in related organs, consistent with systemic glucocorticosteroid activity. In animal tolerance studies, administration of five times the recommended dose resulted in physical signs such as wetness of the inner and outer pinna, attributed to the physical presence of the excess product. Due to the potential for systemic risk, official labeling notes that caution is required when using the product in dogs with impaired hepatic function.

Emergency Actions and Seeking Urgent Help

In the event of accidental human exposure, regulatory documentation mandates specific immediate actions. If accidental human ingestion occurs, the patient must seek medical advice immediately. For accidental human ocular exposure, the eyes must be flushed thoroughly with water for 10 to 15 minutes, and medical advice should be sought if symptoms develop after the flushing procedure. Management of documented systemic overexposure is generally symptomatic and supportive, as no specific pharmacological antidote is listed in the official prescribing information.

Therapeutic Uses of Osurnia

Osurnia is commonly used for managing external ear conditions in dogs. This medication is relevant in conditions characterized by acute episodes where symptoms may intensify temporarily due to a complex infection and inflammatory response.

The formulation is applied in clinical settings that involve acute symptom patterns driven by a mixed microbial overgrowth, specifically susceptible strains of bacteria (Staphylococcus pseudintermedius) and yeast (Malassezia pachydermatis). Its dual anti-infective support assists with the management of these pathogens. The treatment is considered relevant for addressing infectious causes while assisting with the management of pronounced symptoms of inflammation.

Osurnia is relevant when short-term symptomatic assistance is needed to manage the patient's physical discomfort and distress. It helps address symptom clusters that may become intense or disruptive, such as aural pain and disruptive head shaking, ultimately contributing to improved day-to-day comfort during symptomatic periods.

Therapeutic Focus: Support for Inflammatory Symptoms

The medication is commonly used to help with symptoms related to inflammatory or irritative states, such as marked swelling and redness, providing support that helps ease the overall symptom burden in dogs experiencing acute flare-ups.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Osurnia

The eligibility profile for Osurnia is strictly defined by government regulatory documents, confirming it is authorized exclusively for use in dogs.

Eligibility Scope

Classification	Population or Condition
Contraindicated	Dogs with hypersensitivity to any active substance or excipient.
Contraindicated	Dogs with known tympanic perforation (perforated eardrum).
Contraindicated	Pregnant, lactating, or breeding animals.
Contraindicated	Cats or other non-canine species, and dogs with generalised demodicosis.
Use Not Established	Dogs less than 2 months of age or weighing less than 1.4 kg.
Conditional Use	Dogs with impaired hepatic function or endocrine disorders (e.g., diabetes mellitus).

Eligibility Classifications (High-Level)

Official regulatory documents establish three main eligibility classifications: Contraindicated (absolute prohibition), Not Established (use not recommended due to insufficient data), and Conditional/Caution (use with precaution or caution).

Resulting eligibility structure The eligibility structure is rigorously defined by regulatory bodies to ensure the product is only administered to the approved canine patient population, explicitly excluding dogs with compromised ear anatomy, hypersensitivity, or specific systemic and reproductive health statuses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Osurnia (Florfenicol, Terbinafine, Betamethasone Dipropionate otic gel) defines interactions based primarily on local administration restrictions and the risk of systemic absorption.

Pharmacodynamic and Absorption Interactions

Interacting Substance/Condition	Officially Documented Outcome
Additional Corticosteroid Treatments	Should be avoided due to the potential for additive systemic effects arising from the absorption of the Betamethasone component.
Inflammation/Compromised Barrier	Can increase the percutaneous absorption of the product's components, which increases the potential for systemic effects like adrenocortical suppression.
Systemic Medicines	No specific systemic drug-drug interactions are formally listed as contraindicated in the regulatory labels.

Procedural and Topical Product Restrictions

Restriction Type	Official Requirement
Ear Cleaners	Compatibility has not been demonstrated with ear cleaners other than saline (sodium chloride) solution, restricting their concurrent topical use.
Ear Cleaning Timing	The ear cleaning procedure should not be repeated for 21 days after the second product administration.

Population-Specific Interaction Notes

Use with caution is specified for dogs with impaired hepatic function due to relevance for drug component clearance. Caution is also advised in dogs with suspected or confirmed endocrine disorders (e.g., diabetes mellitus) related to the systemic effects of the Betamethasone component.

Mechanism of Action

How Osurnia Works: The Triple-Action Mechanism

The biological activity of the components involves the simultaneous engagement of three distinct molecular mechanisms that influence microbial proliferation and local inflammatory signaling.

Disrupting Fungal Cell Membrane Synthesis

This mechanism engages the antifungal component, which acts as a non-competitive inhibitor of the key fungal enzyme squalene epoxidase. By blocking this step, the drug prevents the production of ergosterol, a critical structural lipid in the fungal cell membrane. This action results in ergosterol depletion and toxic squalene accumulation within the fungal cell, leading to loss of cellular integrity, which constitutes a fungicidal action.

Inhibiting Bacterial Protein Production

The antibacterial mechanism centers on binding to the 50S subunit of the bacterial ribosome. This specific interaction inhibits the enzyme peptidyl transferase, thereby blocking the formation of new bacterial proteins and stopping the elongation of peptide chains. This functional blockade results in a bacteriostatic physiological effect.

Suppressing the Inflammatory Cascade

The corticosteroid mechanism involves agonism of the intracellular Glucocorticoid Receptor (GR). This molecular interaction leads to the genomic suppression of genes responsible for producing numerous pro-inflammatory mediators, such as prostaglandins and leukotrienes. The physiological consequence is a modification of local tissue responses, including decreased vasodilation and a suppression of the signaling cascades that modulate nociception (sensory irritation).

Dosage and Administration Information

How Osurnia is Used: Official Administration Guidelines

The usage of Osurnia (Florfenicol, Terbinafine, Betamethasone Acetate Otic Gel) is based on a structured, fixed-interval protocol. The primary principles govern the route, dosing schedule, and required administration context.

Administration Protocol

Property	Official Instruction
Route of Administration	Auricular Use (Otic): Applied topically into the external ear canal.
Dosing Schedule	One full tube (containing 1.0 mL of gel) is administered per affected ear at each application.
Frequency and Timing	Treatment consists of two total administrations, separated by an interval of seven days.
Contextual Condition	The product must be administered by a veterinary professional (in-clinic).

Procedural Requirements and Restrictions

The treatment protocol includes specific procedural steps that must be adhered to for proper use. The ear canal is required to be cleaned and dried immediately prior to receiving the first dose. After the gel is applied, the base of the ear should be gently massaged to facilitate the proper distribution of the viscous gel along the ear canal surface.

A key restriction is the post-application constraint on cleaning; the ear canal must not be cleaned for a prescribed duration following the initial administration to allow the drug components to remain in contact with the tissue. Safety has not been established for use in young dogs less than two months of age or weighing under 1.4 kg.

This two-dose, fixed-interval approach establishes the standardized administration method.

Recent Clinical Evidence

Research evidence / Overview of studies for Osurnia

The research evidence used to evaluate Osurnia comes primarily from formal, multicenter Randomized Controlled Trials (RCTs) conducted across numerous centers. These trials involved blinding researchers and owners to which treatment was being given. The product was studied for its use in specific, regulated conditions involving the external ear canal in dogs.

Evidence for use in Acute Otitis Externa

Research has explored the use of the product in dogs presenting with conditions characterized by acute or disruptive episodes of otitis externa. The studies monitored dogs during periods of heightened symptom activity where susceptible strains of bacteria (Staphylococcus pseudintermedius) and yeast (Malassezia pachydermatis) were identified. The clinical trials compared the product both against a placebo (the gel base without the active components) and against other established ear treatments.

In these trials, researchers used structured scoring systems, such as the Total Clinical Score (TCS), which is a key measurement used in research exploring how symptoms change over time. This score tracks several outcomes related to physical discomfort and inflammation, including redness (erythema), swelling, pain, and the presence of exudate. The studies also examined the microbial status by looking for the absence of the target pathogens via cytology and culture at defined points after treatment. Findings describe patterns observed in the studies related to changes in these scores and the status of the target microorganisms.

What remains uncertain includes how long the measured clinical and microbial findings might persist beyond the observation period. The primary trials focused on the short-term study of the acute infection. Long-term effects are not fully established, and the research does not provide data on the ability to prevent future episodes of otitis externa.

Evidence for use in Acute Exacerbations of Recurrent Otitis Externa

The evidence for recurrent otitis externa episodes was evaluated in a defined subpopulation of dogs included in the main RCTs. These dogs were experiencing an acute flare-up of a condition previously noted for having cycles of stability and flare-ups. This analysis helped the studies monitored patterns specifically in conditions involving periods of heightened symptoms.

The research examined changes in the same core measurements as the acute trials, including the Total Clinical Score and the microbial status. Data show patterns related to how symptoms evolved in this observed population during the study period.

Key Limitations and Areas of Uncertainty

Several research limitation frames apply to the existing evidence. As noted, long-term effects are not fully established, particularly concerning data on underlying conditions related to recurrence. Also, the core research studies were conducted during periods of increased symptom activity where the application of the product was typically preceded by an ear cleaning procedure using saline. The data provide limited information for application without this initial step. Finally, findings describe group patterns, not personal outcomes, meaning research does not determine whether an individual dog will respond in the same way.

Key Studies & References

FOI Summary for the Original Approval of NADA 141-437 (Osurnia) - Animal Drugs @ FDA

Frequently Asked Questions (FAQ)

Common questions about Osurnia (FAQ)

Q: What is the general timeline for seeing an improvement in symptoms after using Osurnia?

A: Studies and official information indicate that the final clinical effect is not immediate. The maximum clinical response observed in trials occurred up to 21 days after the second administration. This timeline confirms that the monitoring period for effectiveness extends well beyond the final application date.

Q: How long is the active medication expected to remain inside the dog's ear canal?

A: The product is formulated to be eliminated slowly through natural mechanical processes within the ear canal. The regulatory instructions specify that the ear should not be cleaned for 45 days after the initial application, which is intended to allow the product to remain in contact with the ear tissue for a prolonged period.

Q: Why is it recommended not to clean the ear canal for 45 days after the initial dose?

A: The official product information specifies that the ear should not be cleaned for 45 days after the first application. This instruction is required to allow the medication to remain in contact with the ear canal, as cleaning the ear before this period may interfere with the intended effectiveness of the product.

Q: Why is restraining the dog important after the application of the gel?

A: Regulatory documents describe restraining the dog as a precaution during and immediately after the application. This is done to minimize post-application head shaking, which helps reduce the potential for the product to splatter and decrease the risk of accidental eye exposure for both humans and the dog.

Q: What are the specific storage requirements for Osurnia before it is administered?

A: According to the official product information, the product must be stored under refrigerated conditions, specifically between 2 C and 8 C (36 F and 46 F). A tube may be removed from the refrigerator and stored at room temperature (up to 25 C or 77 F) for a total period of up to three months before it is used for administration.

Q: Can the use of Osurnia affect blood test results, such as liver enzyme levels?

A: Official reports from clinical trials indicate that elevated liver enzymes, including Alkaline Phosphatase (ALP), were observed as adverse reactions. Elevated liver enzymes are a documented adverse reaction, and regulatory documents note that owners should communicate with their veterinarian regarding the use of the product when testing is performed.

Q: Why is Osurnia a gel formulation instead of a traditional liquid drop?

A: The product is formulated as a viscous gel, a feature designed to help it adhere to the walls of the ear canal. This adherence allows for prolonged contact of the active ingredients with the ear tissue, which is fundamental to the treatment’s two-dose schedule.

Q: Does Osurnia continue to work after the second application is given?

A: Clinical monitoring has indicated that the maximum effect of the treatment may be observed up to 21 days following the second application. The timeline of clinical response observed in studies confirms that the monitoring period extends significantly beyond the date of the final administration.

Q: Is there evidence regarding how long the benefits of Osurnia treatment may last?

A: The clinical trials used to establish the product’s effectiveness primarily focused on the short-term study of acute infections. Official information states that the long-term effects of the treatment, particularly beyond the clinical observation period, have not been fully established.

Q: Does the drug target the root cause of recurring ear issues?

A: The research evidence currently available describes the product's use for treating the acute inflammation and infection found in ear distress. Studies do not provide data regarding the product’s ability to prevent future episodes of otitis externa.

Q: Are there specific long-term health concerns associated with the steroid component in Osurnia?

A: Regulatory documents note that systemic absorption of the topical corticosteroid component has been associated with measurable adrenocortical suppression, which is an interference with the body's natural steroid production. This effect is generally noted in official information as being reversible.

Q: What signs might indicate a systemic reaction to the medication? (e.g., beyond the ear)

A: Regulatory documents list reactions that have been reported outside the ear, such as vomiting, head tilt, and incoordination (ataxia). Product information also includes the recommendation for owners to contact their veterinarian if these signs are observed, as part of the safety information.

Q: Does Osurnia have documented interactions with other commonly prescribed oral medications?

A: The regulatory documents state that no specific systemic drug-drug interactions with other commonly prescribed oral medicines are formally listed as contraindicated.

Q: How does Osurnia dissolve or leave the ear canal over time?

A: The official product information notes that the product is designed to dissolve in ear wax. Following this dissolution, the components are slowly eliminated from the ear through natural mechanical processes.

Q: What inactive ingredients are found in the Osurnia gel formulation?

A: In addition to the three active substances, the gel contains several inactive ingredients, including propylene carbonate, glycerol formal, hypromellose, phospholipid, oleic acid, and BHT. These components are necessary to give the product its viscous gel form and stability.

Q: What type of post-approval experience has been documented for Osurnia?

A: Post-approval adverse event reporting has documented rare reactions, meaning they occur in less than 1 in 10,000 animals treated. These reported reactions include occurrences of deafness, tympanic rupture (ruptured eardrum), internal ear disorders (such as head tilt), incoordination (ataxia), and facial paralysis.

Q: Is Osurnia a product that requires a veterinarian's prescription?

A: Yes. Regulatory guidance indicates this product is classified as a Prescription Only Medicine (POM). Federal law restricts the use of this drug to being applied by or on the order of a licensed veterinarian.

Q: Is there a risk of adrenal gland suppression due to the steroid content in the drug?

A: Systemic absorption of the betamethasone component has been associated with measurable adrenocortical suppression. This is noted as a reversible effect by the official product information.

How should Osurnia be stored and disposed of?

Osurnia must be stored in its original packaging under refrigerated conditions, maintained between 36 F and 46 F (2 C and 8 C). The product’s overall shelf life in its unopened, sealed tube is two years.

For administration comfort, a tube may be removed from refrigeration and stored at room temperature (up to 77 F or 25 C) for a total period of up to three months before it is used. Each tube is designed for a single use.

Disposal of any unused product or waste material must follow local, regional, and national regulations. The product is classified as very toxic to aquatic life, requiring handlers to avoid release to the environment and prevent it from entering drains or waterways. The drug must be stored locked up and kept out of the sight and reach of children.

Osurnia